DK4244221T3 - Prodrug af pyrrolidonderivater som glucokinase-aktivator - Google Patents

Prodrug af pyrrolidonderivater som glucokinase-aktivator

Info

Publication number
DK4244221T3
DK4244221T3 DK22782445.5T DK22782445T DK4244221T3 DK 4244221 T3 DK4244221 T3 DK 4244221T3 DK 22782445 T DK22782445 T DK 22782445T DK 4244221 T3 DK4244221 T3 DK 4244221T3
Authority
DK
Denmark
Prior art keywords
prodrugging
glucokinase activator
pyrrolidone derivatives
pyrrolidone
derivatives
Prior art date
Application number
DK22782445.5T
Other languages
English (en)
Inventor
Fuxing Tang
Jin She
Li Chen
Guanghua Lv
Xiangle Jin
Original Assignee
Hua Medicine Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hua Medicine Shanghai Ltd filed Critical Hua Medicine Shanghai Ltd
Application granted granted Critical
Publication of DK4244221T3 publication Critical patent/DK4244221T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DK22782445.5T 2021-09-15 2022-09-15 Prodrug af pyrrolidonderivater som glucokinase-aktivator DK4244221T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111079620 2021-09-15
CN202211093895 2022-09-08
PCT/CN2022/118947 WO2023040937A1 (en) 2021-09-15 2022-09-15 Prodrug of pyrrolidone derivatives as glucokinase activator

Publications (1)

Publication Number Publication Date
DK4244221T3 true DK4244221T3 (da) 2026-02-23

Family

ID=83505858

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22782445.5T DK4244221T3 (da) 2021-09-15 2022-09-15 Prodrug af pyrrolidonderivater som glucokinase-aktivator

Country Status (31)

Country Link
US (2) US12054477B2 (da)
EP (2) EP4244221B1 (da)
JP (1) JP7751731B2 (da)
KR (1) KR20240044465A (da)
CN (1) CN117940419A (da)
AR (1) AR127064A1 (da)
AU (1) AU2022346020A1 (da)
CA (1) CA3231566A1 (da)
CL (1) CL2024000738A1 (da)
CO (1) CO2024002748A2 (da)
DK (1) DK4244221T3 (da)
EC (1) ECSP24020925A (da)
ES (1) ES3063045T3 (da)
FI (1) FI4244221T3 (da)
GE (1) GEP20267848B (da)
HR (1) HRP20260241T1 (da)
IL (1) IL311237A (da)
JO (1) JOP20240055A1 (da)
LT (1) LT4244221T (da)
MA (1) MA62175B1 (da)
MD (1) MD4244221T2 (da)
MX (1) MX2024003068A (da)
PE (1) PE20240933A1 (da)
PL (1) PL4244221T3 (da)
PT (1) PT4244221T (da)
RS (1) RS67759B1 (da)
SI (1) SI4244221T1 (da)
SM (1) SMT202600065T1 (da)
TW (1) TW202328107A (da)
WO (1) WO2023040937A1 (da)
ZA (1) ZA202402086B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021243646A1 (en) * 2020-06-04 2021-12-09 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with hepatic impairment
AR132113A1 (es) * 2023-03-13 2025-05-28 Hua Medicine Shanghai Ltd Forma sólida de derivados de pirrolidona como activador de glucoquinasa
IL325046A (en) 2023-06-06 2026-02-01 Hua Medicine Shanghai Ltd Activates glucokinase for cognitive disorders and neurodegenerative diseases
AU2024400384A1 (en) 2023-12-14 2026-07-09 Hua Medicine USA Inc. Pharmaceutical formulation comprising glucokinase activator and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
WO2009126782A1 (en) 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US20120058937A9 (en) * 2008-04-15 2012-03-08 Tsrl, Inc. Prodrugs of Neuraminidase Inhibitors
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772541B2 (en) 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
US9388168B2 (en) * 2012-12-25 2016-07-12 Hua Medicine Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine
HK1252693A1 (zh) 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Egfr抑制剂及其使用方法
WO2017066705A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
DK3556354T3 (da) 2016-12-15 2025-08-04 Hua Medicine Shanghai Ltd Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf
US11358940B2 (en) 2017-04-20 2022-06-14 The Regents Of The University Of California K-Ras modulators
BR112020024269A2 (pt) * 2018-05-31 2021-02-23 Hua Medicine (Shanghai) Ltd. combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ifm Due有限公司 用於治療與sting活性相關之病況的化合物及組合物
US10689360B1 (en) 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
US11008303B2 (en) 2019-01-30 2021-05-18 Insilico Medicine Ip Limited TLR 9 inhibitors
WO2022040604A1 (en) 2020-08-21 2022-02-24 BioAge Labs, Inc. Use of dp1 receptor antagonists for the treatment of viral respiratory tract infections and dysregulated immune response in aged and aging patients

Also Published As

Publication number Publication date
PE20240933A1 (es) 2024-04-30
EP4244221B1 (en) 2025-12-10
RS67759B1 (sr) 2026-03-31
HRP20260241T1 (hr) 2026-04-10
MD4244221T2 (ro) 2026-04-30
LT4244221T (lt) 2026-02-25
JP7751731B2 (ja) 2025-10-08
US20230322738A1 (en) 2023-10-12
CA3231566A1 (en) 2023-03-23
EP4244221A1 (en) 2023-09-20
MA62175B1 (fr) 2026-02-27
JP2024533536A (ja) 2024-09-12
PT4244221T (pt) 2026-02-11
KR20240044465A (ko) 2024-04-04
GEP20267848B (en) 2026-01-26
FI4244221T3 (fi) 2026-02-19
US20240336597A1 (en) 2024-10-10
IL311237A (en) 2024-05-01
EP4714442A2 (en) 2026-03-25
MX2024003068A (es) 2024-03-27
CO2024002748A2 (es) 2024-03-27
CN117940419A (zh) 2024-04-26
AR127064A1 (es) 2023-12-13
EP4714442A3 (en) 2026-06-03
SMT202600065T1 (it) 2026-03-09
ZA202402086B (en) 2024-11-27
SI4244221T1 (sl) 2026-04-30
TW202328107A (zh) 2023-07-16
AU2022346020A1 (en) 2024-03-21
ECSP24020925A (es) 2024-04-30
WO2023040937A1 (en) 2023-03-23
PL4244221T3 (pl) 2026-04-20
JOP20240055A1 (ar) 2024-03-14
GEAP202416483A (en) 2024-04-25
US12054477B2 (en) 2024-08-06
ES3063045T3 (en) 2026-04-15
CL2024000738A1 (es) 2024-08-30

Similar Documents

Publication Publication Date Title
DK4129989T3 (da) Nitrilderivater, der virker som inhibitorer af dipeptidylpeptidase-1 og anvendelse deraf
DK4069691T3 (da) Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
DK3630724T3 (da) Substituerede indolinderivater som inhibitorer af virusreplikation af denguevirus
EP4120820A4 (en) CRYSTALLINE PSILACETIN DERIVATIVES
CU20180019A7 (es) Derivados de heteroarilo como inhibidores de parp
DK3692039T3 (da) Enantiomerer af substituerede thiazoler som antivirale forbindelser
DK3350163T3 (da) Mono- eller disubstituerede indolderivater som hæmmere af denguevirusreplikation
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
CR20140294A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
DK3436435T3 (da) Substituerede indolderivater som inhibitorer af replikation af denguevirus
EP4129987A4 (en) Crystal form of free alkali of nitrogen-containing aromatic derivatives
IL311237A (en) Prodrug of pyrrolidone derivatives as glucokinase activator
DK3833665T3 (da) Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
DK4514473T3 (da) Heterocykliske forbindelser som modulatorer af bcl6 som ligand-styrede nedbrydningsmidler
DK4038063T3 (da) Heterocykliske forbindelser til inhibering af tyk2-aktiviteter
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
PL4301748T3 (pl) Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu
DK4000424T3 (da) Sammensætning af nikotinpose
EP3917926C0 (en) IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, THEIR USES
DK4229056T3 (da) Triazolpyridinylforbindelser som kinasehæmmere
DK4192813T3 (da) Inhibitorer af transglutaminaser
DK4396183T3 (da) Substituerede s-alaninatderivater
EP4308572C0 (en) NEW THIENOPYRIMIDINONE DERIVATIVES
DK4228755T3 (da) Tetrazol-derivater som trpa1-hæmmere
DK3826983T3 (da) Anvendelse af substituerede 2-thiazoliner som nitrificeringshæmmere